Our results confirmed for the first time that miR-1275 inhibited epirubicin resistance via regulation of the miR-1275/MDK/AKT axis to lessen the properties of cancer stem cells, indicating that miR-1275 has potential to be a suppressor in BC chemoresistance. This evidence concerns the gene MDK and breast cancer.